In addition to the development of humanized pan-allele-targeting antibodies, future research should focus on designing drug delivery strategies that specifically target the tumor immune microenvironment, developing novel SIRPα-targeting therapeutics, and elucidating the molecular mechanisms of other SIRP family members. This evidence concerns the gene SIRPA and neoplasm.